Business Description
Agios Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US00847X1046
Share Class Description:
STU:8AP: Ordinary SharesCompare
Compare
Traded in other countries / regions
AGIO.USAAGIO.Mexico8AP.Germany0HB0.UK IPO Date
2013-08-08Description
Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development plan for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 16.52 | |||||
| Equity-to-Asset | 0.91 | |||||
| Debt-to-Equity | 0.04 | |||||
| Debt-to-EBITDA | -0.15 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 14.26 | |||||
| Beneish M-Score | -1.19 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -13.5 | |||||
| 3-Year EPS without NRI Growth Rate | -9.9 | |||||
| 3-Year FCF Growth Rate | -8.6 | |||||
| 3-Year Book Growth Rate | 36 | |||||
| Future 3-5Y Total Revenue Growth Rate | 92.34 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 63.38 | |||||
| 9-Day RSI | 64.68 | |||||
| 14-Day RSI | 64.99 | |||||
| 6-1 Month Momentum % | 20.11 | |||||
| 12-1 Month Momentum % | 106.93 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 8.99 | |||||
| Quick Ratio | 8.77 | |||||
| Cash Ratio | 8.41 | |||||
| Days Inventory | 2295.73 | |||||
| Days Sales Outstanding | 31.8 | |||||
| Days Payable | 1283.6 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 6.9 | |||||
| Shareholder Yield % | 0.42 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 89.38 | |||||
| Operating Margin % | -1238.1 | |||||
| Net Margin % | 2051.38 | |||||
| FCF Margin % | -1004.2 | |||||
| ROE % | 71.3 | |||||
| ROA % | 62.91 | |||||
| ROIC % | -116.85 | |||||
| ROC (Joel Greenblatt) % | -521.13 | |||||
| ROCE % | -40.71 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 5.23 | |||||
| Price-to-Owner-Earnings | 5.48 | |||||
| PS Ratio | 102.93 | |||||
| PB Ratio | 2.08 | |||||
| Price-to-Tangible-Book | 2.08 | |||||
| EV-to-EBIT | -6 | |||||
| EV-to-Forward-EBIT | -0.81 | |||||
| EV-to-EBITDA | -6.09 | |||||
| EV-to-Revenue | 74.32 | |||||
| EV-to-Forward-Revenue | 24.25 | |||||
| EV-to-FCF | -7.4 | |||||
| Price-to-Net-Current-Asset-Value | 3.73 | |||||
| Price-to-Net-Cash | 4.04 | |||||
| Earnings Yield (Greenblatt) % | -16.67 | |||||
| FCF Yield % | -9.75 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Agios Pharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 30.127 | ||
| EPS (TTM) (€) | 10.133 | ||
| Beta | -0.26 | ||
| Volatility % | 52.18 | ||
| 14-Day RSI | 64.99 | ||
| 14-Day ATR (€) | 1.452341 | ||
| 20-Day SMA (€) | 51.695 | ||
| 12-1 Month Momentum % | 106.93 | ||
| 52-Week Range (€) | 19.1 - 57.5 | ||
| Shares Outstanding (Mil) | 57.03 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Agios Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Agios Pharmaceuticals Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Agios Pharmaceuticals Inc Frequently Asked Questions
What is Agios Pharmaceuticals Inc(STU:8AP)'s stock price today?
The current price of STU:8AP is €55.00. The 52 week high of STU:8AP is €57.50 and 52 week low is €19.10.
When is next earnings date of Agios Pharmaceuticals Inc(STU:8AP)?
The next earnings date of Agios Pharmaceuticals Inc(STU:8AP) is 2025-02-14 Est..
Does Agios Pharmaceuticals Inc(STU:8AP) pay dividends? If so, how much?
Agios Pharmaceuticals Inc(STU:8AP) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers